Granisetron Transdermal Patch for Prophylaxis of Delayed CINV

Summary

Transdermal granisetron has been shown to as effective as oral/ intravenous granisetron when administered with or without dexamethasone. However, it has not been evaluated specifically against the delayed response of chemotherapy-induced nausea and vomiting (CINV) in comparison with palonosetron, as the complete response for the delayed phase was not reported in the comparative study by Seol et al (Support Care Cancer 2016;24:945-952). Thus, transdermal granisetron needs to be compared with palonosetron as part of dual and triple therapy in the delayed phase of CINV. This investigator-initiated study aims to compare the efficacy of granisetron transdermal patch and palonosetron combined with NK-1 receptor antagonist and dexamethasone in the prevention of delayed CINV in Chinese breast cancer patients who received high emetic or moderate emetic chemotherapy.

Timeline

Start

2021-06-10

Primary completion

2022-06-10

Completion

2023-12-30

Publications

• Liu X, Meng Y, Du Y, Mu Y, Li G, Li H, Guan X, Zhang J. Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial. Oncologist. 2026 Feb 5;31(3):oyag007. doi: 10.1093/oncolo/oyag007.

Drugs

Indications